GlaxoSmithKline: ViiV Healthcare Reports Positive HIV Trial Results

Date : 08/22/2019 @ 8:10AM
Source : Dow Jones News
Stock : Pfizer Inc (PFE)
Quote : 36.5  0.0 (0.00%) @ 1:02PM

GlaxoSmithKline: ViiV Healthcare Reports Positive HIV Trial Results

Glaxosmithkline (LSE:GSK)
Historical Stock Chart

1 Month : From Aug 2019 to Sep 2019

Click Here for more Glaxosmithkline Charts.
   By Ian Walker 

GlaxoSmithKline PLC's (GSK.LN) joint-venture company ViiV Healthcare said Thursday that a global phase 3 "Atlas-2M" study of rilpivirine for the treatment of HIV met its primary endpoint.

ViiV Healthcare--which is jointly owned by Pfizer Inc. (PFE)--said the study showed a combination of cabotegravir and rilpivirine administered every eight weeks is similar to a four-week administration.

"The Atlas-2M study results mean that people living with HIV could maintain viral suppression with six total treatments per year, instead of a daily oral treatment 365 times per year," Viiv Healthcare's Head of Research & Development Kimberly Smith said.


Write to Ian Walker at


(END) Dow Jones Newswires

August 22, 2019 02:55 ET (06:55 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest PFE Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.